Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases

被引:74
|
作者
Keeling, Kim M. [1 ]
Bedwell, David M. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Microbiol, Gregory Fleming James Cyst Fibrosis Res Ctr, Birmingham, AL 35294 USA
关键词
MESSENGER-RNA DECAY; TRANSLATIONAL TERMINATION EFFICIENCY; PREMATURE STOP MUTATIONS; CYSTIC-FIBROSIS PATIENTS; ALPHA-L-IDURONIDASE; DYSTROPHIN EXPRESSION; CRYSTAL-STRUCTURE; READ-THROUGH; IN-VITRO; AMINOGLYCOSIDE;
D O I
10.1002/wrna.95
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Suppression therapy is a treatment strategy for genetic diseases caused by nonsense mutations. This therapeutic approach utilizes pharmacological agents that suppress translation termination at in-frame premature termination codons (PTCs) to restore translation of a full-length, functional polypeptide. The efficiency of various classes of compounds to suppress PTCs in mammalian cells is discussed along with the current limitations of this therapy. We also elaborate on approaches to improve the efficiency of suppression that include methods to enhance the effectiveness of current suppression drugs and the design or discovery of new, more effective suppression agents. Finally, we discuss the role of nonsense-mediated mRNA decay (NMD) in limiting the effectiveness of suppression therapy, and describe tactics that may allow the efficiency of NMD to be modulated in order to enhance suppression therapy. (c) 2011 John Wiley & Sons, Ltd. WIREs RNA 2011 2 837-852 DOI: 10.1002/wrna.95
引用
收藏
页码:837 / 852
页数:16
相关论文
共 50 条
  • [41] Pharmaceuticals Targeting Nonsense Mutations in Genetic DiseasesProgress in Development
    Steven M. Rowe
    John P. Clancy
    BioDrugs, 2009, 23 : 165 - 174
  • [42] Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations
    Liguori, Ludovica
    Monticelli, Maria
    Allocca, Mariateresa
    Mele, Bruno Hay
    Lukas, Jan
    Cubellis, Maria Vittoria
    Andreotti, Giuseppina
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (02)
  • [43] No-nonsense: Alltrna Touts tRNA Therapeutics to Treat Thousands of Diseases
    Grinstein J.D.
    Genetic Engineering and Biotechnology News, 2023, 5 (01): : 396 - 400
  • [44] Nonsense Suppression Therapy: An Emerging Treatment for Hereditary Skin Diseases
    Yu, Jiangfan
    Tang, Bingsi
    He, Xinglan
    Zou, Puyu
    Zeng, Zhuotong
    Xiao, Rong
    ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [45] Therapeutic targeting of TP53 nonsense mutations in cancer
    Strandgren, Charlotte
    Wiman, Klas G.
    UPSALA JOURNAL OF MEDICAL SCIENCES, 2024, 129
  • [46] Ataluren: A 'no-nonsense' approach for pulmonary diseases
    Loudon, John A.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2013, 26 (03) : 398 - 399
  • [47] DIAGNOSIS OF NONSENSE MUTATIONS IN ASPERGILLUS-NIDULANS BY MEANS OF PHENOTYPIC SUPPRESSION
    MARTINELLI, SD
    ROBERTS, TJ
    HEREDITY, 1983, 50 (APR) : 209 - 210
  • [48] Introducing sense into nonsense in treatments of human genetic diseases
    Linde, Liat
    Kerem, Batsheva
    TRENDS IN GENETICS, 2008, 24 (11) : 552 - 563
  • [49] Allele-specific therapy: suppression of nonsense mutations by readthrough inducers
    Floquet, Celia
    Rousset, Jean-Pierre
    Bidou, Laure
    M S-MEDECINE SCIENCES, 2012, 28 (02): : 193 - 199
  • [50] IDENTIFICATION OF AMINO ACIDS INCORPORATED DURING SUPPRESSION OF CFTR NONSENSE MUTATIONS
    Thrasher, K.
    Xue, X.
    Benson, D.
    Mobley, J.
    Renfrow, M. B.
    Keeling, K. M.
    Bedwell, D.
    PEDIATRIC PULMONOLOGY, 2019, 54 : S201 - S201